BioSpace News Archive

Edentulism or loss of tooth is a condition described by the partial or complete loss of teeth because of damage or infections, for example, tooth rot, tooth injury, or gum illness.

The global circular dichroism spectrometer market is anticipated to grow due to presence of several regional and international players.

Leading players are developing and implementing advanced technology in neonatal dialysis treatment such as continuous renal replacement therapy by using dialysis machine, augmenting the growth

Modern Living with kathy ireland® discusses Valor’s unique service areas, hormone balancing, and how patients can get started in improving their health.

TLC announced that the Central Drugs Standard Control Organization of India has approved the New Drug Application of Amphotericin B Liposome for Injection 50mg for immediate importation per approved usage and indication, to aid in the country’s emergency of acute liposomal amphotericin B shortage.

- Gryphon Investors (“Gryphon”), a leading middle-market private equity firm, announced today that it has signed a definitive agreement to sell its portfolio company CORA Health Holdings Corp. (“CORA,” “CORA Physical Therapy,” or “the Company”) to an affiliate of H.I.G. Capital. Gryphon originally invested in the Company in July 2016 .

Results of Split-Face Study to Determine the Efficacy and Safety of 2.5% Agarose Gel Filler for the Correction of Nasolabial Folds Published in Peer Reviewed Journal

LAVA Therapeutics N.V., a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy, announced that Stephen Hurly, chief executive officer, will present at the 2021 Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 11:30 a.m. ET.

Boston Scientific Corporation announced it has completed CE Mark for the EXALT™ Model B Single-Use Bronchoscope, a single-use device designed for bedside procedures in the intensive care unit, operating room and bronchoscopy suite.

TherapeuticsMD, Inc., an innovative, leading women’s healthcare company, announced that the Company submitted a supplemental New Drug Application for BIJUVA capsules, 0.5 mg/100 mg, to the U.S. Food and Drug Administration.